Comparison of Trends, Mortality, and Readmissions After Insertion of Left Ventricular Assist Devices in Patients < 65 Years Vs ≥65 Years

End-stage heart failure that is refractory to medical therapy constitutes 5% of total heart failure population but has profound effects on quality of life with dismal survival.1 Palliative options with or without ionotropic therapies remained the only route for majority of these patients, with only few eligible for orthotropic heart transplant. The advent of durable left ventricular assist devices (LVADs) changed this paradigm after showing drastically improved outcomes, and are now widely accepted therapeutic options for eligible patients.

Source: The American Journal of Cardiology - May 12, 2020 Category: Cardiology Authors: Aniket S. Rali, Sagar Ranka, Prakash Acharya, Tyler Buechler, Robert Weidling, Ioannis Mastoris, Siva Taduru, Travis Abicht, Nicholas Haglund, Andrew J Sauer, Zubair Shah Source Type: research